Lantheus Holdings (LNTH) risk factors

Item 1A of every Lantheus Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open LNTH in Gloom →

Lantheus Holdings' chart, financials and news, free in your browser.Open LNTH in Gloom →

FY2025 10-K risk factors
52 risks16 new7 dropped17 reworded
Lantheus faces upcoming generic expiration risks for PYLARIFY in May 2026. Executive leadership turnover occurred with CEO Brian Markison retiring. The company expanded its share buyback program to $400.0 million.
Filed Feb 26, 2026
FY2024 10-K risk factors
43 risks
Dependence on PMF partners and third-party manufacturers for just-in-time radiopharmaceutical distribution.
Filed Feb 26, 2025